Cargando…

肺癌合并其他器官多原发癌的临床特点分析

BACKGROUND AND OBJECTIVE: With the popularization of chest computed tomography (CT) early screening for lung cancer, the detection rate of lung cancer combined with multiple primary malignancies (MPM) in other organs has been increasing. In this paper, the incidence, pathological characteristics, di...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849037/
https://www.ncbi.nlm.nih.gov/pubmed/33478184
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.01
_version_ 1783645237326905344
collection PubMed
description BACKGROUND AND OBJECTIVE: With the popularization of chest computed tomography (CT) early screening for lung cancer, the detection rate of lung cancer combined with multiple primary malignancies (MPM) in other organs has been increasing. In this paper, the incidence, pathological characteristics, diagnosis and treatment characteristics and prognosis were discussed and analyzed to provide research basis for improving the clinical diagnosis and treatment of this disease. METHODS: From September 2011 to September 2015, a total of 5, 570 patients with lung cancer were treated in Jiangsu Cancer Hospital. The clinicopathological characteristics of 61 patients with lung cancer combined with MPM in other organs were retrospectively analyzed. RESULTS: The incidence rate of lung cancer combined with MPM in other organs in this group was 1.1%, of which 15 cases were synchronous MPM (SMPM), 46 cases were metachronous MPM (MMPM). Colorectal cancer, breast cancer and thyroid cancer accounted for the top three of lung cancer combined with MPM in other organs. The overall 5-year survival rate was 39.3% and 71.4% of patients died from metastasis or recurrence of lung cancer. Multivariate analysis showed that the clinical stage of lung cancer patients, the order of occurrence of lung cancer and other tumors, the treatment status of patients with other organ tumors and the presence of epidermal growth factor receptor (EGFR) gene mutation were important factors for the survival of the patients. CONCLUSION: The incidence rate of lung cancer combined with MPM in other organs is not uncommon. Lung cancer is the main cause of death compared with other organs tumors. Patients with advanced lung cancer, SMPM, lung cancer first, combined with tumor only receiving palliative treatment and without EGFR gene mutation had a poor prognosis.
format Online
Article
Text
id pubmed-7849037
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-78490372021-02-04 肺癌合并其他器官多原发癌的临床特点分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: With the popularization of chest computed tomography (CT) early screening for lung cancer, the detection rate of lung cancer combined with multiple primary malignancies (MPM) in other organs has been increasing. In this paper, the incidence, pathological characteristics, diagnosis and treatment characteristics and prognosis were discussed and analyzed to provide research basis for improving the clinical diagnosis and treatment of this disease. METHODS: From September 2011 to September 2015, a total of 5, 570 patients with lung cancer were treated in Jiangsu Cancer Hospital. The clinicopathological characteristics of 61 patients with lung cancer combined with MPM in other organs were retrospectively analyzed. RESULTS: The incidence rate of lung cancer combined with MPM in other organs in this group was 1.1%, of which 15 cases were synchronous MPM (SMPM), 46 cases were metachronous MPM (MMPM). Colorectal cancer, breast cancer and thyroid cancer accounted for the top three of lung cancer combined with MPM in other organs. The overall 5-year survival rate was 39.3% and 71.4% of patients died from metastasis or recurrence of lung cancer. Multivariate analysis showed that the clinical stage of lung cancer patients, the order of occurrence of lung cancer and other tumors, the treatment status of patients with other organ tumors and the presence of epidermal growth factor receptor (EGFR) gene mutation were important factors for the survival of the patients. CONCLUSION: The incidence rate of lung cancer combined with MPM in other organs is not uncommon. Lung cancer is the main cause of death compared with other organs tumors. Patients with advanced lung cancer, SMPM, lung cancer first, combined with tumor only receiving palliative treatment and without EGFR gene mutation had a poor prognosis. 中国肺癌杂志编辑部 2021-01-20 /pmc/articles/PMC7849037/ /pubmed/33478184 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.01 Text en 版权所有©《中国肺癌杂志》编辑部2021 This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 临床研究
肺癌合并其他器官多原发癌的临床特点分析
title 肺癌合并其他器官多原发癌的临床特点分析
title_full 肺癌合并其他器官多原发癌的临床特点分析
title_fullStr 肺癌合并其他器官多原发癌的临床特点分析
title_full_unstemmed 肺癌合并其他器官多原发癌的临床特点分析
title_short 肺癌合并其他器官多原发癌的临床特点分析
title_sort 肺癌合并其他器官多原发癌的临床特点分析
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849037/
https://www.ncbi.nlm.nih.gov/pubmed/33478184
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.01
work_keys_str_mv AT fèiáihébìngqítāqìguānduōyuánfāáidelínchuángtèdiǎnfēnxī
AT fèiáihébìngqítāqìguānduōyuánfāáidelínchuángtèdiǎnfēnxī
AT fèiáihébìngqítāqìguānduōyuánfāáidelínchuángtèdiǎnfēnxī
AT fèiáihébìngqítāqìguānduōyuánfāáidelínchuángtèdiǎnfēnxī
AT fèiáihébìngqítāqìguānduōyuánfāáidelínchuángtèdiǎnfēnxī